Last Price | 1618.00 | Max Price | 1733.50 |
Min Price | 1376.60 | 1 Year return | 12.55 |
Avg. Target | 0.00 | Expected Return | -100.00 % |
Sector | Health Care | Subsector | Pharmaceuticals |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 0 | ||
Annual report 2012 |
GlaxoSmithKline (GSK) is a large research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GlaxoSmithKline’s business employs approximately 100,000 people in 116 countries. GlaxoSmithKline’s stocks are traded in London and the company is a component of the FTSE 100-index (ISIN: GB0009252882/ Symbol: GSK).
Contact info:Street: 980 Great West Road Zip Code: LondonCity: LondonCountry: Great BritainPhone: 44 (0)20 8047 5Email: in.investorqueries@gsk.comWebsite: www.gsk.com
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 33,754 | 615,634 | 5.48 % |
2020 | 34,099 | 638,070 | 5.34 % |
2021 | 34,114 | 727,968 | 4.69 % |
2022 | 29,324 | 787,273 | 3.72 % |
2023 | 0 | 0 | 0.00 % |
GlaxoSmithKline and SK bioscience start late-stage trial for COVID-19 vaccine candidate
High dividend yield GlaxoSmithKline
GlaxoSmithKline is one of the top English dividend stocks
Analysts expect over 2019 rising revenue GlaxoSmithKline, quite high dividend
Analysts: more sales GlaxoSmithKline, high dividend yield
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
GlaxoSmithKline has located her head office London. GlaxoSmithKline's core business is the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the period 2006-2016. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.
Over the past year the company' stock gained around 14 percent. Over the past 5 years GlaxoSmithKline' stock rose at around 7 percent in value. GlaxoSmithKline's revenues between 2011 and 2015 were relatively stable and moved between 2643,1 billion GBp and 2392,3 billion GBp. The net results between 2011 and 2015 were far from constant and fluctuated between 511,08 billion GBp and 269 billion GBp.
GlaxoSmithKline paid out dividends in the past 5 years. Over the past 5 years GlaxoSmithKline's dividend yield was at around 382 percent per year.
As per the end of 2015 the English company's balance sheet equaled 5344,6 billion GBp. The total debt was around 4833,2 billion GBp. This is 90,43 percent of the total balance sheet. At the end of 2016 the English company was traded with a price/earnings-ratio of around 24. So investors paid 24 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the English stock can be seen as a value stock.
At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 6539,82 billion GBp. At the end of 2015 the English company had around 4,83 billion stocks listed on the stock exchange(s).
All GlaxoSmithKline's annual reports can be found here. More information about GlaxoSmithKline can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
23,923
|
27,889
|
30,186
|
30,821
|
33,754
|
34,099
|
Costs |
15,501
|
26,976
|
28,654
|
27,198
|
29,109
|
28,350
|
Profit |
8,422
|
913
|
1,532
|
3,623
|
4,645
|
5,749
|
Margin of profit |
35.20
|
3.27
|
5.08
|
11.75
|
13.76
|
16.86
|
ROI |
164.69
|
81.23
|
-2252.94
|
83.10
|
40.73
|
39.41
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
5,114
|
1,124
|
-68
|
4,360
|
11,405
|
14,587
|
Debt |
48,332
|
57,957
|
56,449
|
53,706
|
68,287
|
65,844
|
Total assets |
53,446
|
59,081
|
56,381
|
58,066
|
79,692
|
80,431
|
Solvency |
9.57
|
1.90
|
-0.12
|
7.51
|
14.31
|
18.14
|
Cash |
5,905
|
4,986
|
3,911
|
3,958
|
4,786
|
6,370
|
Cashflow |
2,569
|
6,497
|
6,918
|
8,421
|
8,020
|
8,441
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.05
|
0.11
|
0.12
|
0.16
|
0.12
|
0.13
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
1367.34
|
1577.72
|
1335.81
|
1506.21
|
1796.90
|
Eps |
0.23
|
0.39
|
0.91
|
1.16
|
1.43
|
Price/earnings-ratio |
5944.96
|
4045.44
|
1467.92
|
1298.46
|
1131.47
|
Dividend |
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
Dividend % |
0.07 %
|
0.06 %
|
0.07 %
|
0.07 %
|
0.06 %
|
Payout % |
4.35
|
2.56
|
1.10
|
0.86
|
0.70
|
Book value |
0.29
|
-0.02
|
1.11
|
2.88
|
3.63
|
Market to book |
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow per stock |
1.65
|
1.74
|
2.14
|
2.02
|
2.10
|
Stocks |
3,928
|
3,966
|
3,938
|
3,963
|
4,024
|
Market Cap |
5.371.031.97
|
6.257.802.82
|
5.260.873.96
|
5.968.492.68
|
6.510.815.82
|
Date
|
Price
|
---|---|
28 Aug 2024
|
1618.00
|
26 Aug 2024
|
1602.50
|
23 Aug 2024
|
1597.00
|
11 Aug 2024
|
1565.50
|
07 Aug 2024
|
1535.00
|
05 Aug 2024
|
1547.00
|
01 Aug 2024
|
1512.00
|
30 Jul 2024
|
1557.00
|
26 Jul 2024
|
1523.50
|
23 Jul 2024
|
1524.50
|
16 Jul 2024
|
1498.00
|
10 Jul 2024
|
1505.00
|
09 Jul 2024
|
1509.50
|
04 Jul 2024
|
1503.50
|
02 Jul 2024
|
1595.00
|
26 Jun 2024
|
1595.00
|
21 Jun 2024
|
1733.50
|
19 Jun 2024
|
1733.50
|
14 Jun 2024
|
1733.50
|
11 Jun 2024
|
1733.50
|
01 Jun 2024
|
1733.50
|
31 May 2024
|
1733.50
|
27 May 2024
|
1733.50
|
21 May 2024
|
1733.50
|
15 May 2024
|
1733.50
|
10 May 2024
|
1733.50
|
07 May 2024
|
1733.50
|
01 May 2024
|
1673.00
|
22 Apr 2024
|
1590.00
|
18 Apr 2024
|
1590.00
|